| Zacks Company Profile for Sarepta Therapeutics, Inc. (SRPT : NSDQ) |
|
|
| |
| • Company Description |
| Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
Number of Employees: 1,372 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $17.39 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 7,880,755 shares |
| Shares Outstanding: 97.71 (millions) |
| Market Capitalization: $1,699.23 (millions) |
| Beta: 0.49 |
| 52 Week High: $138.81 |
| 52 Week Low: $10.42 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-14.33% |
-15.84% |
| 12 Week |
-16.27% |
-23.95% |
| Year To Date |
-85.70% |
-86.85% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Douglas S. Ingram - President; Chief Executive Officer
M. Kathleen Behrens - Chairwoman of the Board
Ian M. Estepan - Executive Vice President; Chief Financial Officer
Richard Barry - Director
Deirdre Connelly - Director
|
|
Peer Information
Sarepta Therapeutics, Inc. (CORR.)
Sarepta Therapeutics, Inc. (RSPI)
Sarepta Therapeutics, Inc. (CGXP)
Sarepta Therapeutics, Inc. (BGEN)
Sarepta Therapeutics, Inc. (GTBP)
Sarepta Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 803607100
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/05/25
|
|
Share - Related Items
Shares Outstanding: 97.71
Most Recent Split Date: 7.00 (0.17:1)
Beta: 0.49
Market Capitalization: $1,699.23 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.31 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-3.60 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 7.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 17.33% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/05/25 |
|
|
|
| |
